NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Tuesday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Up 0.5 %

Shares of NURO opened at $4.40 on Tuesday. The company’s fifty day simple moving average is $4.20 and its 200 day simple moving average is $4.06. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $4.73. The company has a market cap of $9.03 million, a price-to-earnings ratio of -0.96 and a beta of 2.18.

Institutional Investors Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. Renaissance Technologies LLC acquired a new stake in NeuroMetrix, Inc. (NASDAQ:NURO) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned 0.57% of NeuroMetrix as of its most recent SEC filing. Institutional investors own 19.40% of the company’s stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.